The Company’s basic policy calls for continued stable dividends while taking into comprehensive consideration securing necessary funds for long-term business development. Internal reserves are utilized to enhance the corporate constitution, targeting sustained future growth, through investment in areas such as R&D and production facilities. At the same time, the Company also recognizes appropriate distribution of earnings reflecting revenue levels to be an important topic of management. Based on the "ASKA Pharmaceutical Holdings Takes Action to Implement Management That is Conscious of Cost of Capital and Share Price" announced in November 2023, the Company has shifted to a performance-linked profit-sharing method, indicating a consolidated dividend payout benchmark ratio of 30%.
Based on the above considerations, and reflecting recent trends in business performance, the Company plans to pay year-end dividends of 30 yen per share, combined with the interim dividends of 25 yen per share already paid. This will result in annual dividends of 55 yen per share. The Company plans to distribute earnings in the next period through an increase in annual dividends to 55 yen per share (interim dividends of 27 yen per share and year-end dividends of 28 yen per share).
(As of May 12, 2025)